CI vs INCY: fair value comparison
The Cigna Group and Incyte Corporation · Updated 2026-09-07
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, CI currently sits closer to the top of our discount ranking. INCY carries the stronger quality grade.
| CI | INCY | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $282.52 | $126.75 |
| 12-month range | $244.41–$289.26 | $93.48–$125.01 |
| Sector rank | #34 of 113 Healthcare | #37 of 113 Healthcare |
| Quality grade | F | A |
| Leverage | Moderate | Low |
| Margin trend | Contracting | Stable |
| Revenue growth | Strong | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Uptrend |
| DCF cross-check | Undervalued | Overvalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: CI fair value analysis · INCY fair value analysis